@mastersthesis{10336/4247,
author = {Molano Niño, Blanca Lucia},
year = {2013},
url = {http://repository.urosario.edu.co/handle/10336/4247},
abstract = {Apnea of prematurity is a common condition that occurs in 85% of infants less than 34 weeks gestational age and in 95-100% of under 28 weeks. Regarding birth weight, occurs in 92% of those weighing less than 1250 grams and 50% of those weighing less than 1500 grams. Since 2003, Colombia approved the use of caffeine citrate for the prevention and treatment of apnea of prematurity, based on evidence.
Methods: We conducted an intervention study comparing caffeine citrate with aminophylline for the prevention and management of apnea in preterm infants under 35 weeks of age.
Results: 118 preterm infants inlcuyeron of which 18.6% were under 28 weeks, 79.7% at 34 weeks and two 1.7% greater than or equal to 34.1 weeks. 56 infants received caffeine citrate. Of these, 33.9% and 66.1% prophylactic, therapeutic, 28 (23.7%) received aminophylline and 34 (28.8%) did not receive either drug.
Caffeine citrate showed fewer side effects compared with aminophylline (p <0.01).
Discussion: caffeine citrate, administered prophylactically or therapeutically, superior results showed statistically significant compared with aminophylline and untreated controls, for the prevention and treatment of apnea of prematurity, presenting also minor effects side.},
keywords = {Aminofilina},
keywords = {Cafeina},
keywords = {Apnea},
keywords = {Prematuro},
keywords = {Metilxantinas},
title = {Cafeina vs aminofilina para la apnea del prematuro: estudio randomizado},
publisher = {Universidad del Rosario},
keywords = {apnea of prematurit},
keywords = {caffeine},
keywords = {aminophylline},
keywords = {preterm},
keywords = {methylxanthines},
keywords = {PICU},
}